BASE PROBIOTIQUE TRIPLE ACTION
Natural health product licensed in Canada
- Licence holder
- Les Emballages Façoteck
- NPN or DIN-HM
- 80118523
- Status
- Active licence
- Licence date
- 10 May 2022
- Revision date
- 4 October 2022
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Lactiplantibacillus plantarum Source : Lactobacillus plantarum - Cellule entière | 1 Milliards d'UFC | Not calculated |
| Pediococcus acidilactici Source : Pediococcus acidilactici - Whole Cell | 1 Milliards d'UFC | Not calculated |
| Bifidobacterium animalis subsp. lactis | 1.8 Milliards d'UFC | Not calculated |
| Lactococcus lactis Source : Lactococcus lactis - Cellule entière | 7.2 Milliards d'UFC | Not calculated |
Non-medicinal ingredients
D-Mannitol, Cellulose microcristalline, Trehalose, Sucrose, Amidon de maïs, Gomme de gellane, Phosphate de potassium, dibasique, Stéarate de magnésium, Citrate de sodium, Phosphate de potassium monobasique, Chlorure de sodium, Dextrose, Ascorbate de sodium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Could promote a favorable gut flora. Helps support intestinal/gastrointestinal health. Source of Probiotics. Reduces whole gut transit time/helps to accelerate intestinal transit time. Supports digestion by reducing transit time. Reduces frequency of functional gastrointestinal symptoms (e.g. constipation, irregularity, flatulence). Promotes bowel movement. Helps provide gentle relief of constipation and/or irregularity. Helps improve quality of life by relieving IBS symptoms. Helps reduce symptoms of lactose intolerance such as abdominal pain and flatulence. Helps relieve the symptoms of irritable bowel syndrome (IBS) (abdominal pain, bloating, distension). Helps improve IBS-related quality of life in patients with IBS and diarrhea. Helps to manage patients' IBS symptoms that impacts their quality of life. Helps improve quality of life in IBS patients by supporting gut health and improving gut comfort. Helps to improve gut-related stress/discomfort from IBS in 6 weeks. Helps improve quality of life in patients with diarrhea-predominant irritable bowel syndrome.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80118523
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging